TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01719510

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~* one swab for GBS detection by real-time PCR~* the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~2. A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding.
Study: NCT00633945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02392754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)
Description: The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
Study: NCT02375347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chickpea Enhanced Diet (Short term)
Description: Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14.
Study: NCT02552147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal placebo
Study: NCT03634397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less-Impaired Arm Training
Description: Participants receive virtual reality and manipulation training in their less impaired arm.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Contralesional Arm Comparison
Description: Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
Study: NCT00730613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Cycles of escalating cell dose infusions up to the target cell dose of 10(8)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: At the time of excess pathology samples documenting response/relapse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: CSF generated at the time of each T-cell dose
Study: NCT00787072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8075
Description: Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT00079339

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT01982799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral acetaminophen/hydrocodone + ibuprofen
Description: vicodin/ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral acetaminophen/hydrocodone + ibuprofen
Description: vicodin/ibuprofen
Study: NCT00079339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT02349945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follitropin alpha
Description: All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follitropin alpha
Description: All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle.
Study: NCT04181112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT using retention enema

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT using retention enema
Study: NCT04312256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
Study: NCT00940875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po on days 15-28 of each 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250mg/m2/day on days 1 and 8 of each 4 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
Study: NCT02884037

Intervention type: DRUG
Intervention: Rifaximin group 1
Description: Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
Study: NCT02547272

Intervention type: PROCEDURE
Intervention: Nasal and rectal bacterial samples
Description: Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
Study: NCT01943682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Comparison of Different doses of drug
Study: NCT05096039

Intervention type: DRUG
Intervention: Sacubitril/valsartan
Description: Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'

Intervention type: DRUG
Intervention: ACEI or ARB and no sacubitril/valsartan
Description: Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
Study: NCT01189110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy using TENS unit Stim Flex 400A
Description: Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Auriculotherapy using TENS unit Stim Flex 400A
Description: Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
Study: NCT02420249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong training
Description: Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
Study: NCT01210326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extaction
Description: TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: testicular sperm extraction
Description: testicular sperm extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: testicular sperm aspiration
Description: testicular sperm aspiration
Study: NCT01038453

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 35 µg per day
Description: Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo 2 tablet, once a day,

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D3) 70 µg
Description: Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery.
Study: NCT04832295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photo-supported conversations
Description: Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Medication, psychological treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: Medication, psychological treatment
Study: NCT01349452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir 0.15% Ophthalmic gel

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Artificial tear
Description: Artificial tear 5 times per day
Study: NCT05775783

Intervention type: PROCEDURE
Intervention: Transvenous lead extraction
Description: Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.

Intervention type: PROCEDURE
Intervention: Transvenous lead extraction
Description: Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
Study: NCT02768883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respira Sano
Description: The intervention is all three components: clinic + home + community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respira Sano
Description: The intervention is all three components: clinic + home + community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respira Sano
Description: The intervention is all three components: clinic + home + community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respira Sano
Description: The intervention is all three components: clinic + home + community.
Study: NCT01516749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
Study: NCT04197167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Diagnostic procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Spectroscopy
Description: This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
Study: NCT02729467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
Study: NCT03782571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon a Test 1
Description: 1-DAY ACUVUE® MOIST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon a Test 1
Description: 1-DAY ACUVUE® MOIST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon a Test 1
Description: 1-DAY ACUVUE® MOIST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon a Test 1
Description: 1-DAY ACUVUE® MOIST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 2
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM
Study: NCT02480647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: 20μg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: 20μg/day.
Study: NCT04577131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly check-in
Description: Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
Study: NCT03735043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac output by ccNexfin ©
Description: Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
Study: NCT02964702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy Device T-01
Study: NCT03782571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 2
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 2
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A Test 2
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM
Study: NCT02454504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study: NCT01199978

Intervention type: RADIATION
Group type: OTHER
Intervention: Fractionated proton radiation
Description: Given daily for approximately 5.5 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: 25mg or 50mg daily, oral administration, for approximately 6 months.
Study: NCT01418404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noxious TS
Description: hot, cold alternately, noxious TS in study A

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Innocuous TS
Description: warm, cool alternately, Innocuious TS in study A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency of Noxious TS
Description: High Frequency of Noxious TS in study B

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Frequency of Noxious TS
Description: Low Frequency of Noxious TS in study B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity of Noxious TS
Description: High Intensity of Noxious TS in study C

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity of Noxious TS
Description: Low Intensity of Noxious TS in study C
Study: NCT03054337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03396068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone HCl
Description: Lurasidone HCl will be given twice a day by mouth
Study: NCT02274090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel consist of drug without the active component.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Metformin gel
Description: Metformin gel consist of active component.
Study: NCT01327612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: Administered by intravenous infusion Q2W or Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: Administered by intravenous infusion Q2W or Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: Administered by intravenous infusion Q2W or Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Administered by intravenous infusion Q3W or Q4W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Administered by intravenous infusion Q3W or Q4W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
Study: NCT01070576

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01908751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sliding Hip Screw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sliding Hip Screw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cancellous Screws

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cancellous Screws

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Placebo
Study: NCT03908892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanthoxylum nitidum tincture
Description: Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline ointment
Description: Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline ointment
Description: Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
Study: NCT01821105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: All patients will receive whole body PET scans (chest-abdomen-pelvis).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: All patients will receive CT scans of the abdomen and pelvis with contrast.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer-aided detection/diagnosis
Description: Undergo computer-aided detection/diagnosis during surgery
Study: NCT00202189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide
Description: Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.